8-K: Keros Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Keros Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting clinical progress and a strengthened cash position.

Summary

• Keros Therapeutics reported a net loss of $40.2 million for the fourth quarter and $153.0 million for the full year ended December 31, 2023.
• This compares to a net loss of $29.7 million for the fourth quarter and $104.7 million for the full year ended December 31, 2022.
• The increased losses are primarily due to increased research and development expenses and investments to support clinical and corporate goals.
• The company generated $0.2 million in revenue for the year ended December 31, 2023, from a manufacturing technology transfer agreement.
• Research and development expenses were $37.5 million for the fourth quarter and $135.3 million for the year ended December 31, 2023.
• General and administrative expenses were $9.1 million for the fourth quarter and $34.8 million for the year ended December 31, 2023.
• Keros' cash and cash equivalents were $331.1 million as of December 31, 2023, compared to $279.0 million as of December 31, 2022.
• The company expects its cash and cash equivalents, along with proceeds from a January 2024 offering, to fund operations into 2027.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the company's clinical progress, strong cash position, and extended cash runway. However, the significant net losses and reliance on future funding temper the overall sentiment.

Positives

• The company has a strong cash position of $331.1 million as of December 31, 2023.
• A recent public offering in January 2024 further strengthened the company's financial position.
• The company expects its current cash reserves to fund operations into 2027.
• Keros has made significant clinical progress across its pipeline, advancing multiple programs into Phase 2 trials.
• The company has a diverse pipeline with three clinical assets targeting different therapeutic areas.

Negatives

• Keros reported a significant net loss of $153.0 million for the full year 2023.
• The company's losses increased compared to the previous year, primarily due to increased research and development expenses.
• The company only generated $0.2 million in revenue for the year ended December 31, 2023.

Risks

• The company has a limited operating history and has incurred historical losses.
• Keros is dependent on the success of its product candidates, KER-050, KER-012, and KER-065.
• There is a risk of delays in initiating, enrolling, or completing clinical trials.
• The company faces competition from third parties developing similar products.
• Keros relies on third parties for manufacturing, clinical trials, and preclinical studies.
• The company needs to raise additional funding to complete the development and commercialization of its product candidates.

Future Outlook

Keros expects its current cash and cash equivalents, along with the proceeds from the January 2024 offering, to fund its planned operating expenses and capital expenditure requirements into 2027. The company also anticipates several clinical trial updates and regulatory engagements in the coming quarters.

Management Comments

• In 2023, Keros made continued clinical progress across our pipeline, including commencing our Phase 2 clinical trial evaluating KER-012 in patients with pulmonary arterial hypertension (PAH) and presenting exciting data from our two ongoing Phase 2 clinical trials of KER-050, one in patients with myelodysplastic syndromes (MDS) and one in patients with myelofibrosis, said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer.
• We continue to build on that momentum in 2024, as highlighted by the advancement of our third clinical asset, KER-065, into a Phase 1 healthy volunteer clinical trial at the beginning of this year.
• We look forward to providing updates from the KER-050 and KER-012 programs in the first half of this year.

Industry Context

This announcement reflects the ongoing trend in the biopharmaceutical industry of companies focusing on clinical development and pipeline expansion. Keros' focus on TGF-beta signaling is a notable area of research, and the company's progress in multiple therapeutic areas positions it as a player in the space. The company's ability to secure funding through a public offering is also indicative of investor interest in the sector.

Comparison to Industry Standards

• Keros' increased R&D spending is typical for a clinical-stage biotech company, as they invest heavily in advancing their pipeline.
• The net losses are also common for companies at this stage, as they are not yet generating significant revenue from product sales.
• The cash runway into 2027 is a positive sign, as it provides financial stability for the company to continue its development programs.
• Comparable companies in the clinical-stage biopharma space, such as Acceleron Pharma (acquired by Merck) and Reata Pharmaceuticals (acquired by Biogen), have also experienced similar patterns of high R&D spending and net losses during their development phases.
• The successful public offering is a positive sign for Keros, as it demonstrates investor confidence in the company's potential.

Stakeholder Impact

• Shareholders will be impacted by the financial results and the company's progress in clinical development.
• Employees will be impacted by the company's growth and expansion.
• Patients with the targeted diseases may benefit from the company's therapeutic developments.
• Suppliers and creditors will be impacted by the company's financial performance and operational activities.

Next Steps

• Engage with regulators on the design of the planned Phase 3 clinical trial of KER-050 in patients with MDS in the first half of 2024.
• Report additional data from Part 2 of the ongoing Phase 2 clinical trial of KER-050 in patients with MDS in the second and fourth quarters of 2024.
• Report additional data from the ongoing Phase 2 clinical trial of KER-050 in patients with myelofibrosis in the second and fourth quarters of 2024.
• Provide an update on enrollment of the ongoing Phase 2 clinical trial evaluating KER-012 in patients with PAH in the first half of 2024.
• Report initial data from the ongoing Phase 2 open-label biomarker trial of KER-012 in patients with chronic heart failure in the second half of 2024.
• Report initial data from the ongoing Phase 1 clinical trial of KER-065 in healthy volunteers in the first quarter of 2025.

Key Dates

Keywords

Keros Therapeutics, biopharmaceutical, clinical trials, KER-050, KER-012, KER-065, myelodysplastic syndromes, pulmonary arterial hypertension, myelofibrosis, obesity, neuromuscular diseases, financial results, research and development, cash position